Our Mission: Perform cutting edge basic and translational research enabling medical innovation
- Fueling cures.
The Applied Biomedical Science Institute (ABS Institute) is a 501(c)(3) non-profit organization taking a leading role in basic research and its rapid clinical translation by performing cutting-edge basic and translational research. Importantly, we are developing the infrastructure for early stage biologic drug development and manufacturing. We promote therapeutic and diagnostic translation through our own internal research, collaborations, or licensing activities. The Institute also trains early stage researchers in biomedical research through post-doctoral fellow and internship programs.
Board of Directors
Ronald A. Martell
Ronald Martell is a veteran biopharmaceutical executive and serial entrepreneur, having founded five companies and served on the boards of directors of several others. In February 2022, Ronald became the CEO of Jasper Therapeutics, a biotechnology company focused on hematopoietic cell transplant therapies.
Prior to joining Jasper, Ronald served as the President and CEO of MorphImmune, Inc. (now Immunome, NASDAQ: IMNM), a platform company advancing a highly specific targeting technology that uses a ligand-linked payload to reprogram the immune system. Previously, he was President and CEO of Nuvelution Pharma. He was also Co-Founder and Executive Chairman of Indapta, Orca Bio and Co-Founder and CEO of Achieve Life Sciences, where he led the merger of the company with Oncogenex. Ronald has served as the CEO of three public biopharmaceutical companies, including Sevion and NeurogesX, and has overseen billions of dollars in industry transactions.
Earlier in his career, Ronald served as Senior Vice President of Commercial Operations at ImClone Systems, where he was instrumental in deals with Bristol-Myers Squibb and Merck KGaA and built ImClone Systems’ worldwide operations to market and commercialize Erbitux®. He also served in various leadership positions with Genentech where, as Group Manager, Oncology, he was responsible for building the company’s oncology franchise, including the launch of Herceptin® and Rituxan®.
Ronald is passionate about leading public biopharmaceutical companies in all phases of development and maximizing their potential across the healthcare industry.
James W. Larrick M.D., Ph.D.
Dr. Larrick is Founder, Managing Director, Scientific Director of Panorama Research Institute and Managing Director & Chief Medical Officer of Velocity Pharmaceutical Development. Dr. Larrick holds MD and PhD degrees from Duke University School of Medicine and is a pioneer of the biotechnology industry. He is an outstanding biomedical entrepreneur with an international reputation in cytokines, therapeutic antibodies, molecular biology, and pharmaceutical drug development. He has written or coauthored eight books, over 250 papers/chapters, over 30 patents, and served on the editorial boards of six journals. In 1991, Jim founded the Panorama Institute of Molecular Medicine (PRI) which has incubated more than 20 life science projects, leading to his co-founding more than a dozen companies. To date, PRI-initiated projects and/or companies have led to five IPOs and numerous successful acquisitions.
Vaughn V. Smider M.D., Ph.D.
Dr. Smider is the founder and President of ABS Institute and is an adjunct Professor at the Scripps Research Institute. He previously led a research laboratory in the Molecular Medicine department at Scripps from 2006-2018. Dr. Smider has multiple publications in antibody molecular biology, genetics, and structure, as well as in DNA repair and cancer biology. In these fields he also developed several groundbreaking technologies. He was a founder and CSO of Fabrus (now NASDAQ: ELOX), the first company started in a pharmaceutical company incubator, The Pfizer Incubator, Taurus Biosciences (acquired by Ligand Pharmaceuticals, and now part of Ligand’s spin-out company, OmniAb Inc. (NASDAQ: OABI), and ABS Institute spin-out companies Minotaur Therapeutics and Enkefalos Biosciences. Dr. Smider served on the leadership council for the American Cancer Society, is a founder of the Elizabeth Smider Foundation, and serves as an advisor to several biotechnology and pharmaceutical companies. Dr. Smider received his M.D. and Ph.D. (Immunology) degrees from the Stanford University School of Medicine.
For Dr. Smider’s publications, see:
David Rabuka, Ph. D.
David Rabuka is the founder and CEO of Acrigen Biosciences, a company developing safe and efficient methods for gene editing therapy. Prior to founding Acrigen, David was the Global Head of Research and Development, Chemical Biology at Catalent Biologics with overall R&D responsibility to oversee continued research and development of biotherapeutics, as well as overseeing strategy, resource allocation, scientific oversight of preclinical and clinical studies. In 2008, David founded and acted as President and Chief Scientific Officer of Redwood Bioscience Inc. David joined Catalent Biologics in 2014, following Catalent’s acquisition of Redwood Bioscience Inc. David is currently active with the Berkeley Catalyst Fund as a venture partner and life science partner.
David’s scientific areas of expertise include chemical synthesis, drug delivery, translational research, Chemistry Manufacturing and control (CMC), protein chemistry and bioconjugation. David received a Ph.D. in Chemistry at the University of California, Berkeley as a Chevron Fellow in the lab of Professor Carolyn Bertozzi where his research included developing and applying protein bioconjugation technology to cell surface modification. Prior to pursuing his Ph.D., David worked at the Burnham Institute synthesizing complex glycans and later at Optimer Pharmaceuticals, which he joined as an early employee, focused on the development of glycan and macrolide based antibiotics.
David graduated with honors B.S. in Chemistry and Biochemistry from the University of Saskatchewan where he received the Dean’s Science Award and holds a M.S. in Chemistry from the University of Alberta. He is an author on over 45 major publications as well as numerous books chapters and over 50 patents.